Author

Viktoria Ekström-Rydén

Observed names: V. Ekström-Rydén, V. Rydén, Viktoria Ekstrom Ryden, Viktoria Rydén

Institutions: Uppsala University, Uppsala University Hospital, Science for Life Laboratory

Observed institutions: Uppsala University, Uppsala University Hospital, Science for Life Laboratory

ORCID: 0009-0000-6053-3392

Observed ORCID: 0009-0000-6053-3392

OpenAlex ID: A5126079596

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

2024 · Cecilia Olsson Ladjevardi, Anthoula Koliadi, et al. · Frontiers in Oncology · 19

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

2024 · Cecilia Olsson Ladjevardi, Marcus Skribek, et al. · Cancer Immunology Immunotherapy · 18

The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta‐analysis

2023 · Viktoria Rydén, Ali Inan El‐Naggar, et al. · Pigment Cell & Melanoma Research · 15

Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

2023 · Cecilia Olsson Ladjevardi, Anthoula Koliadi, et al. · Cancer Medicine · 13

LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial

2026 · O. Hamid, V. Ekström-Rydén, et al. · Nature Communications · 3

Prior CTLA-4 blockade as associated with a hyperactive immunosuppressive signature and limited response to subsequent immunotherapy in melanoma.

2026 · Omid Hamid, Tanja Lovgren, et al. · Journal of Clinical Oncology

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies

2026 · V. Ekström-Rydén, A. Carneiro, et al. · ESMO Open

Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

2026 · Hanna Grauers Wiktorin, Viktoria Ekström-Rydén, et al. · Biomarker Research

Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

2026 · Hanna Grauers Wiktorin, Viktoria Ekström-Rydén, et al. · Figshare

Additional file 1 of Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

2026 · Hanna Grauers Wiktorin, Viktoria Ekström-Rydén, et al. · Figshare

Additional file of Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

2026 · Hanna Grauers Wiktorin, Viktoria Ekström-Rydén, et al. · Figshare

988O A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma

2024 · O. Hamid, V. Rydén, et al. · Annals of Oncology

Works count: 12

Citation count: 68

H-index: 4

I10-index: 4